Quarterly ResultJul 29, 2026, 07:17 AM
Axogen Q2 Revenue +23.1% to $69.7M; Raises FY26 Guidance
AI Summary
Axogen, Inc. reported strong second quarter 2026 financial results, with revenue increasing 23.1% year-over-year to $69.7 million. The company raised its full-year 2026 revenue guidance to at least 24% growth, targeting $279 million. Despite a GAAP net loss of $1.5 million, adjusted net income grew to $7.3 million, and the company highlighted progress in strategic priorities, including clinical study publications and a minority investment in Trace Biosciences.
Key Highlights
- Q2 2026 Revenue was $69.7 million, an increase of 23.1% year-over-year.
- Full-year 2026 revenue guidance raised to at least 24% growth, or $279 million.
- Net loss for Q2 2026 was $1.5 million, or $0.03 per share, compared to net income of $0.6 million in Q2 2025.
- Adjusted net income was $7.3 million, or $0.12 per share, compared to $5.7 million in Q2 2025.
- Cash and cash equivalents, restricted cash, and investments totaled $113.4 million as of June 30, 2026.
- Gross margin was 72.7% in Q2 2026, down from 74.2% in Q2 2025.
- Published REPOSE clinical study results and initiated Nerve-RESTORE study.
- Acquired a minority ownership stake in Trace Biosciences for nerve-specific imaging technology.
Price Impact
More from AXGN